Outcome of Patients with Relapsed/Refractory AIDS-Related Lymphoma Diagnosed 1999–2008 and Treated with Curative Intent in the AIDS Malignancy Consortium

摘要

No comparative studies exist for relapsed/refractory (rel/rfr) AIDS-related lymphomas (ARLs). To determine practices over the last decade and to assess the outcomes of salvage chemotherapy with curative intent and autologous stem cell transplantation (ASCT), we retrospectively evaluated treatment outcomes in patients with rel/rfr ARL who were treated in 13 national AIDS Malignancy Consortium (AMC) sites between 1999 and 2008 (N=88). The most commonly used second line therapies were ICE (n=34), dose adjusted EPOCH (n=17), and ESHAP (n=11). The odds of achieving a response were lower for those with non-Hodgkin lymphoma (NHL) than those with HL and for those with primary refractory disease than those with relapse. Overall survival (OS) was significantly longer for those with relapsed disease compared to those with refractory disease and for those with non-Burkitt NHL compared to those with Burkitt. OS was longer in patients who underwent ASCT compared to those who did not (1-year OS: 63.2% vs. 37.2%). However, among 32 patients (36%) who achieved CR/PR after second-line therapy 1-year OS was not different between the 2 groups (87.5% for ASCT vs. 81.8% for non-ASCT). Long-term survival in some patients with rel/rfr ARL may be possible without transplant, although transplant remains the standard of care for chemotherapy sensitive disease.